STXBP3 和 GOT2 可预测急性移植物排斥反应中的免疫活性。

STXBP3 and GOT2 predict immunological activity in acute allograft rejection.

机构信息

Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China.

出版信息

Front Immunol. 2022 Dec 1;13:1025681. doi: 10.3389/fimmu.2022.1025681. eCollection 2022.

DOI:10.3389/fimmu.2022.1025681

PMID:36532048

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9751189/

Abstract

BACKGROUND

Acute allograft rejection (AR) following renal transplantation contributes to chronic rejection and allograft dysfunction. The current diagnosis of AR remains dependent on renal allograft biopsy which cannot immediately detect renal allograft injury in the presence of AR. In this study, sensitive biomarkers for AR diagnosis were investigated and developed to protect renal function.

METHODS

We analyzed pre- and postoperative data from five databases combined with our own data to identify the key differently expressed genes (DEGs). Furthermore, we performed a bioinformatics analysis to determine the immune characteristics of DEGs. The expression of key DEGs was further confirmed using the real-time quantitative PCR (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemical (IHC) staining in patients with AR. ROC curves analysis was used to estimate the performance of key DEGs in the early diagnosis of AR.

RESULTS

We identified glutamic-oxaloacetic transaminase 2 (GOT2) and syntaxin binding protein 3 (STXBP3) as key DEGs. The higher expression of STXBP3 and GOT2 in patients with AR was confirmed using RT-qPCR, ELISA, and IHC staining. ROC curve analysis also showed favorable values of STXBP3 and GOT2 for the diagnosis of early stage AR.

CONCLUSIONS

STXBP3 and GOT2 could reflect the immunological status of patients with AR and have strong potential for the diagnosis of early-stage AR.

摘要

背景

肾移植后急性同种异体排斥反应（AR）导致慢性排斥反应和移植物功能障碍。目前 AR 的诊断仍然依赖于肾移植活检，而在 AR 存在的情况下，活检不能立即检测到肾移植损伤。在这项研究中，我们研究和开发了用于保护肾功能的 AR 诊断的敏感生物标志物。

方法

我们分析了五个数据库的术前和术后数据，结合我们自己的数据，以确定关键的差异表达基因（DEGs）。此外，我们进行了生物信息学分析，以确定 DEGs 的免疫特征。我们使用实时定量 PCR（RT-qPCR）、酶联免疫吸附试验（ELISA）和免疫组织化学（IHC）染色进一步证实了 AR 患者关键 DEGs 的表达。ROC 曲线分析用于评估关键 DEGs 在 AR 早期诊断中的性能。